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2Abstract
Tissue-engineered skeletal muscle can serve as a physiological model of natural muscle and a
potential therapeutic vehicle for rapid repair of severe muscle loss and injury. Here we describe
a platform for engineering and testing highly functional biomimetic muscle tissues with a
resident satellite cell niche and capacity for robust myogenesis and self-regeneration in vitro.
Using a mouse dorsal window implantation model and transduction with fluorescent intracellular
calcium indicator, gCaMP3, we non-destructively monitored, in real time, vascular integration
and the functional state of engineered muscle in vivo. During a 2 week period, implanted
engineered muscle exhibited a steady ingrowth of blood-perfused microvasculature along with
an increase in amplitude of calcium transients and force of contraction. We also demonstrated
superior structural organization, vascularization, and contractile function of fully differentiated vs.
undifferentiated engineered muscle implants. The described in vitro and in vivo models of
biomimetic engineered muscle represent enabling technology for novel studies of skeletal
muscle function and regeneration.
Significance Statement
Engineering of highly functional skeletal muscle tissues can provide accurate models of muscle
physiology and disease and aid treatment of various muscle disorders. Previous tissue
engineering efforts have failed short of recreating structural and contractile properties of native
muscle in vitro. Here we describe the creation of biomimetic skeletal muscle tissues with
structural, functional, and myogenic properties characteristic of native muscle and contractile
stress values that surpass those of neonatal rat muscle. When implanted and real-time imaged
in live animals, engineered muscle grafts undergo robust vascularization and perfusion, exhibit
continued myogenesis, and show further improvements in intracellular calcium handling and
contractile function. This process is significantly enhanced by myogenic pre-differentiation and
formation of aligned muscle architecture in vitro.
Introduction
Natural skeletal muscle consists of terminally differentiated, highly aligned, and contractile
myofibers and a population of resident muscle stem cells, known as satellite cells (SCs), which
are indispensable for muscle growth (1) and regeneration (2). The ability to create engineered
muscle tissues that mimic the structural, functional, and regenerative properties of native
muscle would enable design of accurate in vitro models for studies of muscle physiology and
development (3, 4) and promote cell-based therapies for muscle injury and disease (5) (6).
Pioneering studies of Vandenburgh (7) and Dennis (8) were the first to demonstrate in vitro
engineering of functional mammalian muscle constructs, followed by other studies reporting that
differentiated engineered muscle can survive and vascularize upon implantation in vivo (9-13).
Simultaneously, various studies have shown that compared to differentiated or committed cells,
undifferentiated SCs are a more potent myogenic cell source with the ability to engraft and
replenish the host satellite cell pool and support future rounds of muscle regeneration (14-16).
Thus, it is likely that for optimal therapy, engineered muscle tissues should fully recreate the
cellular heterogeneity of native muscle and consist of both force-generating, differentiated
myofibers and a functioning SC pool to allow further maturation and regeneration in vivo.
Additionally, for long-term survival and efficient repair, implanted engineered muscle constructs
must rapidly integrate into host vascular system and significantly increase their functional output
compared to pre-implantation levels.
In this study, we utilized primary rat myogenic cells to engineer skeletal muscle tissues
with highly organized architecture and force generating capacity comparable to those of native
muscle. We characterized the temporal dynamics of myogenic processes within engineered
muscle and documented the in vitro formation of a homeostatic tissue state with the co-
existence of highly contractile muscle fibers and functional satellite cells. To continuously
3monitor engineered tissue survival, function, and vascularization after implantation, we
transduced myogenic cells with gCaMP3, a genetic indicator of intracellular Ca2+ concentration
used previously in neurobiological (17) and cardiac (18) research, and implanted the muscle
constructs in a dorsal skinfold chamber in nude mice. The use of this minimally-invasive, in vivo
platform allowed us to simultaneously, in real time, quantify and compare changes in Ca2+
transient amplitude and vascular density between highly differentiated and undifferentiated
engineered muscle implants and to further assess the maintenance of satellite cell pool and
enhancement of contractile function relative to those pre-implantation. Overall, our studies
describe important advances in the field of skeletal muscle tissue engineering and lay
foundation for novel studies of cellular function and signaling in a physiological environment in
real time.
Results
Structure of Engineered Muscle. Engineered muscle bundles (Fig. 1A) were created using a
neonatal rat myogenic cell population that predominantly consisted of Pax7+/MyoD+ activated
satellite cells (SCs) and a small fraction of myogenin+ precursors, but no evidence of endothelial
or smooth muscle cells (Fig. S1). After 2 weeks of culture, engineered bundles consisted of
laminin-surrounded myofibers that occupied the entire tissue volume (Fig. 1B) and a peripheral
layer of vimentin+ fibroblasts that resembled the epimysial connective tissue layer encasing the
myofibers of neonatal hindlimb muscle (Fig. S2A). The interior of both engineered and native
neonatal muscle contained densely packed, highly aligned, multinucleated, and cross-striated
myofibers surrounded by a basal lamina-like matrix consisting of laminin and collagen IV (Fig.
1C). Within the basal lamina, Pax7+ SCs were found residing within a native-like niche, closely
abutting myofiber sarcolemma (Fig. 1C-D, Fig. S2B-C). Overall, the 3D organization of the
engineered muscle bundle highly resembled that of a native muscle fascicle, while lacking
higher-order structures including multi-fascicle organization, tendons, and neurovascular bed.
Myogenesis in Engineered Muscle. We further quantified the temporal changes in cell
proliferation and expression of key myogenic transcription factors (Pax7, MyoD, and myogenin
(MyoG)) during in vitro culture (Fig. S3). At early stages of engineered muscle formation (day 2),
a large majority of Pax7+ cells (~75%) were activated and proliferating as evidenced by their
expression of Ki67 (Fig. S3A and B). Simultaneously, the vast majority of early fusing cells or
newly-formed, multinuclear myotubes expressed MyoD, either without or with MyoG (Fig. S3C
and D). By culture day 14, the cells expressing MyoD alone virtually disappeared and all
myonuclei in the engineered muscle expressed MyoG, either alone (~80%) or together with
MyoD (Fig. S4D). The ~20% MyoG+/MyoD+ myonuclei located at the periphery or within existing
myofibers indicated cells that were either primed for fusion or recently fused. By culture day 14,
Pax7+ cells (Fig. S4A) remained in relatively high numbers (~20% of all cells) and, as expected,
did not co-express MyoG (Fig. S2C). Virtually all of the Pax7+ cells were also MyoD- and
quiescent, with only a small fraction (~1.5%) expressing Ki67, suggesting that the engineered
muscle attained a differentiated, homeostatic state.
The presence of MyoD+ cells in the homeostatic engineered muscle (Fig. S3D)
suggested the existence of continuous cell growth and hypertrophy that in native postnatal
muscle are supported by creation of new myonuclei via secondary fusion of SCs with myofibers
(19). We therefore quantified the temporal changes in myofiber size and SC density at 1, 2, and
4 wks of culture and found significant increase in myofiber diameter (1 wk: 8.73 ± 0.33 µm, 2
wk: 14.9 ± 0.87 µm, 4 wk: 22.2 ± 1.33 µm) accompanied by decreases in SC number per 100
µm of myofiber length (1 wk: 1.22 ± 0.12, 2 wk: 0.75 ± 0.05, 4 wk: 0.52 ± 0.02) (Fig. 1E, Fig. S4)
indicative of a functioning SC pool and continuous myogenesis. After 4 wk of culture, these
4parameters achieved values intermediate between those of neonatal and adult rat muscle
tissues (Fig. 1E).
Function of Engineered Muscle. In response to electrical stimulation, engineered muscle
bundles generated strong twitch contractions that with increase in stimulus frequency fused into
a more forceful tetanic contraction (Fig. 1F, Fig. S5A, Movie S1). As characteristic of native
muscle (20), lengthening of engineered muscle yielded a biphasic increase in the amplitude of
active (contractile) force and a monotonic increase in passive tension (Fig. 1G, Fig. S5B).
Contractile force generating capacity of engineered muscle increased with time of culture (1 wk:
8.83 ± 2.3 and 17.27 ± 3.6 mN, 2 wk: 17.08 ± 1.1 and 28.39 ± 0.92 mN, 4 wk: 22.79 ± 2.1 and
26.75 ± 2.3 mN (twitch and tetanus), Fig. 1H), attaining values more than an order of magnitude
higher than those previously reported for other engineered muscle tissues (8, 11, 21-26).
Specific tetanic force per unit muscle cross-sectional area of 47.9 ± 4.1 mN/mm2 in 4-wk
engineered bundles surpassed values reported for native neonatal rat soleus muscle (44
mN/mm2) (20). Moreover, passive tension during 4-wk culture did not change significantly (Fig.
S5C), yielding high active-to-passive force ratios of ~10-15 (Fig. S5D), characteristic of neonatal
skeletal muscle (20, 27) and, to our knowledge, unmet in previous tissue engineering studies.
Response of Engineered Muscle to In Vitro Injury. To further investigate the SC function
within the engineered muscle, we utilized a cardiotoxin (CTX) injury assay to assess whether
the SCs can support muscle self-repair in vitro. Homeostatic, 2-wk old engineered muscle was
exposed to 0.2 µM CTX for 6 h and allowed to recover for 10 days. Consistent with in vivo
reports (28), the CTX exposure resulted in immediate fragmentation of myofibers, cell death,
and disruption of contractile elements leading to a 4-fold decrease in contractile force
generation (Fig. 2, Fig. S6). In response to injury, SCs in the engineered muscle underwent
robust activation and proliferation such that by 5 days post-injury, initially decreased Pax7+ and
MyoD+ cell numbers significantly increased beyond those present in the pre-injury muscle
accompanied by a significant rise in the percentage of proliferating SCs (Ki67+/Pax7+)  (Fig. 2B,
Fig. S6A-B). By 10 days post-injury, numbers of Pax7+, Ki67+/Pax7+, and MyoD+ cells
decreased while the number of MyoG+ myonuclei, myofiber density, and % cross-striated
myofibers increased to near pre-injury levels (Fig. 2B). The progressive regrowth, differentiation,
and sarcomerogenesis of engineered muscle fibers resulted in steady recovery of both twitch
and tetanic force generation, which by 10 days post-CTX injury reached the near pre-injury
levels (Fig 2B).
Vascularization of Implanted Engineered Muscle. In order to assess the ability of the
engineered muscle to survive and vascularize in vivo, we implanted 2-wk pre-differentiated
(PreD) bundles into a dorsal skinfold window chamber in nude mice (29). For this purpose, we
generated smaller three-bundle constructs anchored within a single 9x9 mm square Cerex®
frame that fit within the window chamber (Fig. 3A). As a comparison group, we implanted
undifferentiated (UnD) muscle bundles cultured for only 2 d without switching to differentiation
media that contained sporadically fusing myotubes and high numbers of Pax7+ and Ki67+ cells
(Fig. S7). Placing the engineered muscle between the thin panniculus carnosus muscle layer of
the dorsal skin and a cover glass window allowed us to non-destructively, in live animals, track
angiogenesis and perfusion of the muscle implant in real time. With time post implantation (PI),
initially avascular muscle bundles underwent rapid invasion by host blood vessels (Fig. 3B,
yellow pseudo-colored region) at a rate that was greater in PreD than in UnD muscle implants,
which showed apparent saturation of vessel ingrowth by 14 d PI (Fig. 3C). Importantly, all
ingrown capillary networks appeared functional and perfused by host blood flow (evident from
red blood cell motion) as early as 7 d PI (Movie S2). Interestingly, while asynchronous
spontaneous twitches recorded at 2 wk PI had no apparent effect on the blood flow through
5ingrown capillaries, occasionally observed spontaneous tetanic contractions appeared to
transiently restrict blood perfusion (Movie S3).
Immunostaining analysis (Fig. 3D) further revealed randomly oriented vessel networks at
the periphery of implanted muscle, while within the implant interior the ingrown capillaries co-
aligned with surrounding myofibers to a degree (4.97 ± 1.8°) characteristic of native neonatal
muscle (Fig. S8). In addition, in transverse cross-sections, endothelialized vessel lumens were
found throughout the full thickness of the implants (Fig. 3E). In agreement with intravital imaging
analysis, cross-sectional lumen density in both PreD and UnD implant regions increased
between 1-wk (PreD: 170 ± 11 per mm2, UnD: 75 ± 10 per mm2) and 2-wk (265 ± 30 per mm2,
UnD: 175 ± 18 per mm2) PI and was significantly higher in PreD implants (Fig. 3F). From cross-
sectional immunostainings, the average rate of vascular ingrowth in PreD muscle bundles was
18.9 ± 2.1 vessels/mm2/d. Further, mean lumen diameter increased with time PI, and after 2 wk
amounted to 7.1 ± 0.2 µm, similar to values measured in native hindlimb muscle (Fig. S9).
Myogenesis in Implanted Engineered Muscle. After 2 wk in vivo, implanted PreD muscle
bundles (identified by GFP+ staining for gCaMP3) remained separated from the underlying host
muscle and appeared to maintain pre-implantation volume and a structure consisting of aligned
cross-striated myofibers surrounded by basal lamina proteins (Fig. 3G-I). Importantly, the
implanted myofibers remained abutted by Pax7+ satellite cells at 2 wk PI, suggesting continued
myogenic capacity of engineered muscle in vivo (Fig. 3J). Compared to pre-implantation values
(i.e., 2-wk in vitro culture (IVC)), PreD bundles at 1 wk PI had less cross-striated myofibers (-
40.0 ± 7%); however, by 2 wk PI, virtually all myofibers exhibited cross-striations (Fig. S10)
while the PreD myofiber diameter became significantly increased (+40.7 ± 5% relative to IVC).
Control UnD muscle bundles that prior to implantation showed only sporadic myofiber formation
(Fig. S7 and S10A), underwent significant myogenesis over 2 weeks PI; however, their myofiber
organization, alignment, diameter, and percent of cross-striated myofibers remained inferior to
those of the PreD implants (Fig. S10B, Fig. S11,).
Function of Implanted Engineered Muscle. To non-destructively monitor viability and
functionality of the engineered muscle in vivo, we lentivirally-transduced intracellular Ca2+
sensor gCaMP3 (17) in isolated myogenic cells which allowed us to record spontaneous and
electrically-induced Ca2+ transients in muscle implant by measuring gCaMP3 fluorescence
(ΔF/F, Fig. S12A-E). Intravital gCaMP3 fluorescence movies during spontaneous twitching of
implanted muscle (Movie S4, Fig. 4A) revealed that after an initial lag period of ~7 d, the PreD
muscle implants exhibited a steady increase in Ca2+ transient amplitude (Fig. 4B). The UnD
implants, with limited functionality at 2 d PI, also exhibited a steady increase in spontaneous
activity and amplitude of Ca2+ transients (Fig. 4B). Measurements of electrically-induced Ca2+
responses in explanted muscle (Movie S5) showed that at 2 wk PI, both PreD and UnD muscle
bundles displayed significantly greater Ca2+ transient amplitudes compared to their IVC and 1
wk PI counterparts (Fig. 4C). Kinetics of gCaMP3 Ca2+ transients were not significantly changed
between 1 and 2 wk PI and were comparable between the two implant groups (Fig. S13A).
Since the implanted engineered muscle underwent robust vascular integration with the
host dorsal skin, it could not be separated from the skin without being damaged. Therefore, to
eliminate host contribution to the measured contractile force, we implanted engineered muscle
bundles in the direction perpendicular to that of the host panniculus carnosus muscle layer (Fig.
S13F-H). Functional measurements in 1 and 2 wk explants revealed robust contractile force
responses in both UnD and PreD groups (Fig. 4D). Specifically, implanted engineered UnD
muscle steadily increased its force generating capacity in vivo, and after 2 wk PI reached values
similar to those measured in the PreD group prior to implantation (Fig. 4E). The implanted PreD
muscle showed no enhancement in contractile force generation during first wk PI; however, its
force generating capacity significantly increased by 2 wk PI, reaching tetanus amplitudes 3.2-
6fold higher than the pre-implantation values. This significant increase in the absolute contractile
force amplitude was associated with an ~3.8-fold increase in specific force, which at 2 wk PI
averaged 65.7 ± 8.9 mN/mm2. Similar to Ca2+ transients, the kinetics of force generation in
muscle implants did not significantly change between 1 and 2 wk PI and was comparable
between the two implant groups (Fig. S13). Overall, measurements of both Ca2+ transient and
active force generation suggested that in addition to robust vascularization, implanted
engineered muscle underwent significant enhancement of contractile function in vivo, beyond
what was achievable in vitro.
Discussion
In this study, we sought to reproduce important aspects of skeletal muscle
organogenesis in vitro and create biomimetic tissue constructs with structural, functional, and
myogenic properties characteristic of native muscle. Optimizing the cellular and extracellular
cues essential for muscle growth and development, we created a 3D culture environment
primed for myogenic maturation. Within this engineered muscle environment, initially
proliferating Pax7+ and MyoD+ cells underwent rapid fusion and formation of aligned MyoG+
myofibers that attained a highly differentiated phenotype and became surrounded by quiescent
Pax7+ SCs residing in native-like niches. Differentiation of SCs during 4-week culture
contributed to myofiber hypertrophy, a process characteristic of postnatal muscle growth (19).
Along with the structural maturation, contractile capacity of engineered muscle increased
beyond specific force values measured in neonatal rat muscle, reaching contractile force
amplitude (~30 mN) 10-100 times higher than previously achieved (8, 11, 21-26).
To assess the self-regenerative capacity of engineered muscle, we perturbed its
homeostatic state by a short exposure to cardiotoxin, causing significant cell death, myofiber
fragmentation, and decline in functional output. Similar to injury response in vivo (30, 31),
quiescent SCs in engineered muscle underwent rapid activation and myogenesis to yield
efficient structural repair and restoration of contractile function, followed by recovery of
myogenic indices to pre-injury values. Collectively, by its ability to support native-like SC
function, the 3D engineered muscle tissue described herein may facilitate systematic in vitro
studies of SC fate during simulated growth, exercise, injury, or disease (30, 32).
To explore the fate of engineered muscle in vivo, we further combined gCaMP3
transduction with dorsal window chamber studies in live mice and non-invasively monitored the
ability of implanted engineered muscle to spontaneously contract, generate Ca2+ transients, and
undergo blood perfusion over a 2 week period post-implantation. Regarding the rapid
development of new fluorescent biosensors of cellular function and signaling (e.g., intracellular
ion concentrations, membrane potential, cAMP, pH, etc. (33, 34)), we expect that similar
experimental frameworks could allow real-time in vivo studies of various cellular processes of
importance for the fields of stem cell and cancer biology, tissue engineering, immunology, and
others. In particular, the described concept of simultaneous monitoring of cell viability,
intracellular Ca2+ concentration, and vascularization within a window chamber environment
could be directly applied to in vivo studies of Ca2+ oscillation-dependent differentiation and
function of the heart, neuronal, pancreatic, intestinal, and other cellular and tissue implants.
In our in vivo studies, implanted engineered muscle, showing no evidence of vascular
cells at the time of implantation, became progressively infiltrated with host blood vessels and, as
evidenced by video-imaging (Movie S2), actively perfused with readily discernible blood cells by
7 days PI. By day 14, the vessel density within the PreD muscle implant (265 ± 30 vessels per
mm2) was comparable to that previously reported for implanted tissue-engineered muscle with
pre-formed vascular structures (11) demonstrating that purely angiogenic vessel ingrowth was
sufficient to support the in vivo survival and function of small size avascular engineered muscles
used in our study. On the other hand, successful survival of large engineered muscles implants
will likely require the development of novel methods for in vitro fabrication of highly aligned,
7functional, and pre-vascularized skeletal muscle tissues. Related, our preliminary data
demonstrate that simple co-encapsulation of myogenic and endothelial cells may significantly
impair contractile function of engineered muscle (Fig. S14), suggesting that angiogenic vessel
ingrowth rather than simple vasculogenesis may be a desired mode of engineered muscle
vascularization, compatible with the formation of biomimetic muscle architecture and function in
vitro.
Previously, various cell-based approaches have been explored for treatment of muscle
injury or disease (30). Specifically, implanted freshly isolated SCs were found to fuse to existing
myofibers, rescue contractile function, and, by homing to the host niche, enhance muscle
capacity for endogenous self-repair (14-16). Still, without development of more efficient methods
for their expansion in vitro (35, 36), implanted SCs may not be able to undergo timely
myogenesis to successfully repair large muscle loss (37) . Implanting readily expandable
myoblasts or pre-differentiated myofibers may accelerate in vivo myogenesis, while co-delivery
of growth factors may improve cell survival and engraftment (12), however, without SCs, such
strategies are likely to provide a limited support for future regenerative events (14, 15, 35). In
the current study, we compared the post-implantation fate of PreD muscle constructs consisting
of differentiated myofibers and functional SCs with UnD constructs consisting of
undifferentiated, proliferative myogenic cells. We found that PreD implants not only exhibited
superior structural and functional maturation (evidenced by larger myofiber diameter, percent
cross-striations, and contractile force, Fig. 4, Fig. S10, Fig. S11) but also attracted significantly
more neovessel ingrowth than UnD implants (Fig. 3C and F), possibly due to the increased
metabolic demand of more functional myofibers (38). Although these studies utilized a small
implant size inadequate for therapeutic muscle replacement, they suggest potential benefits of
implanting a functional engineered muscle in which mature myofibers provide niche-like
environment for satellite cells compared to sole use of undifferentiated myogenic cells.
Despite a steady increase in vascularization (Fig. 3C), the amplitude of spontaneous
Ca2+ transients in engineered muscle implants started to steadily increase (and correlate with
vascular ingrowth (39)) only after an initial lag period of 1 week (Fig. 4B). Furthermore, the
percentage of cross-striated fibers in PreD implants at 1 week PI was decreased compared to
the pre-implantation values (Fig. S10B). This adaptation period may have resulted from
potential tissue damage caused by initial hypoxia upon implantation into the dorsal window
chamber and/or disruption of cell-matrix interactions caused by increased fibrinolysis (in the
absence of the antifibrinolyitc supplement amino-caproic acid present in vitro) (26).
Nevertheless, by 2 weeks PI, continuous vascularization, myogenesis, and differentiation of the
PreD implants led to a ~3-fold increase in force generating capacity compared to pre-
implantation values (Fig. 4E) yielding specific contractile forces of ~70 mN/mm2. This in vivo
recovery of the engineered muscle function and structural organization followed a similar time-
course to that observed in vitro upon CTX-induced injury. Along with the maintenance of
aligned, cross-striated myofiber architecture (Fig. 3I) and satellite cell pool (Fig. 3J),
vascularized engineered muscle implants in our study, for the first time to our knowledge,
exhibited structure, contractile function, and myogenic capacity representative of post-neonatal
skeletal muscle.
In summary, we presented a platform for engineering and studying of highly biomimetic
skeletal muscle tissues with functional satellite cells capable of supporting myogenic and self-
regenerative events characteristic of native muscle. While initially avascular, these engineered
muscle tissues underwent robust vascularization and perfusion, and exhibited continued
myogenesis and improved contractile function in vivo, all of which were significantly enhanced
by myogenic pre-differentiation of tissue constructs in culture. Together, these results lay a
foundation for novel in vitro and in vivo studies of skeletal muscle function, regeneration, and
vasculogenesis and provide a blueprint for future engineering of 3D functional human muscle
microtissues for drug and toxicology studies (4) (40).
8Materials and Methods
All methods are described in detail within Supporting Information Appendix.
Engineering of Muscle Bundles. Large single muscle bundles and smaller tri-bundle muscle
implants were formed within polydimethylsiloxane (PDMS) molds as previously described (26,
41). Cell/hydrogel mixture (Table S1) was injected into the PDMS molds, polymerized at 37°C
for 45 min, and cultured on a rocker at 37°C for up to 4 wks.
In Vitro Cardiotoxin Injury Assay. Following 2 weeks of in vitro culture, differentiated
engineered muscle bundles were exposed to 0.2 µM cardiotoxin (CTX, Cardiotoxin from Naja
mossambica mossambica, Sigma) for 6 hours on a rocker at 37°C. The injured bundles were
then rinsed 3 times to remove the toxin and re-incubated in fresh differentiation medium.
Cardiotoxin-injured bundles were assessed for structural composition and contractile function
immediately after CTX removal ('6h post-CTX’ group) and following culture in differentiation
media for additional 5 or 10 days ('5d post-CTX' and '10d post-CTX’ groups).
Implantation of Engineered Muscle. All animal experiments were approved by the Duke
University ACUC. A circular region (~12 mm) of the forward-facing dorsal skin of nude mice was
dissected away and a tri-bundle muscle construct was laid perpendicular to the muscle on the
rearward-facing skin (Fig. S14), providing a source of host microvessels (29).
Intravital Imaging of Blood Vessels and Intracellular Ca2+ Transients. Intravital recordings
were performed at 5X magnification on days 2, 5, 7, 9, 12, and 14 post-implantation (PI).
Capillary vessels were imaged by a video camera and analyzed from total hemoglobin images
(29). Spontaneous Ca2+ transients reported by gCaMP3 (17) fluorescence were imaged by a
fast CCD camera and analyzed as previously described (25).
In Vitro and Ex Vivo Force Measurements. Engineered muscle constructs were loaded into a
custom-made force measurement setup containing an optical force transducer and a linear
actuator (ThorLabs), as previously described (25, 26, 42). Samples were stimulated (10 ms,
3V/mm pulses) at different frequencies (1-40 Hz), and isometric passive and active (contractile)
forces were measured at different muscle lengths. Kinetics of contraction and specific force
were calculated as previously described (26).
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Fig.1. Structural and functional characterization of in vitro engineered skeletal muscle. (A) Live
image of a 2-wk engineered muscle bundle (~1.5 mm diameter, 1.25 cm long) anchored at ends
by tendon-mimetic Velcro tabs pinned inside polydimethylsiloxane (PDMS) well. (B)
Immunostained bundle cross-section shows F-actin+ myofibers embedded within laminin (Lam)
rich matrix. (C) Structural organization of representative engineered and native neonatal rat
soleus muscles (inset: transverse Col4+ structures present in native but not engineered muscle
are CD31+ blood vessels). SAA, sarcomeric α-actin; Col4, collagen IV. (D) Pax7+ satellite cells
in engineered muscle reside at myofiber sarcolemma. (E) Average myofiber diameter and SC
number per 100 µm myofiber length at 1, 2, and 4 wk of culture compared to native neonatal
(neo) and adult soleus muscles. (F) Dependence of active force amplitude (normalized to that of
single twitch) on stimulus frequency. (G) Dependence of active twitch and passive tension
amplitudes on engineered muscle length (expressed relative to culture length). (H) Absolute and
specific (force per area) twitch (Tw) and tetanus (Tet, 40 Hz) amplitudes in engineered bundles
at 1, 2, and 4 wk of culture. Mean ± SEM; n = 4-10 samples per group (8-10 images per
sample); **P < 0.01 between 4 wk bundle and native muscles; P < 0.05 between denoted
groups.
Fig. 2. Regenerative response of engineered muscle to in vitro cardiotoxin (CTX) injury. (A)
Representative images of engineered muscle structure, and Pax7+ cells with time post-CTX
injury (induced at 14 d of culture). (B) Pax7+, Ki67+/Pax7+ (% of Pax7+), MyoD+, and myogenin
(MyoG)+ cell density, myofiber density, % cross-striated myofibers and twitch and tetanus force
amplitudes shown relative to pre-injury levels at 6 h, 5 d, and 10 d post CTX addition. Mean ±
SEM; n = 3-5 samples per group (6-10 images per sample); *P < 0.05 compared to 2 week
healthy controls; P < 0.05 between denoted groups.
Fig. 3. Vascular integration of implanted engineered muscle. (A) Implanted muscle patch within
the dorsal skin-fold window chamber. (B) Images of total hemoglobin at d 2, 9, and 14 in window
chamber (yellow = implant region). (C) Fold change in blood vessel density (BVD) in the implant
region of pre-differentiated (PreD) and undifferentiated (UnD) bundles with time PI. (D) Vessel
organization at the periphery and interior of muscle implant. CD31 labels endothelial cells. (E)
Cross-section of the muscle implant showing lumens of ingrown blood vessels (arrowheads);
VWF, Von Wilenbrand factor. (F) Increase of cross-sectional BVD from 1 wk PI to 2 wk PI.
Mean ± SEM; n = 8-12 per group; *P < 0.05 from value at d 2, #P < 0.05 between PreD and UnD
groups at same time-point, P < 0.05 between denoted groups. (G) Cross-section of implant
region (GFP-positive myofibers) and underlying host muscle. (H-I) Longitudinal section of
implanted bundle showing aligned and cross-striated myofibers (H) embedded in laminin matrix
(I). (J) Pax7+ satellite cells (arrowheads) are found at the periphery of implanted myofibers.
Fig. 4. Calcium transients and force generation of implanted engineered muscle. (A)
Representative intravital snapshots of a gCaMP3 movie recorded during spontaneous activity of
an implanted muscle bundle. Traces below panels show time course of gCaMP3 signal from a
small bundle region (square) with lines denoting the snapshot times. Average amplitudes of in
vivo spontaneous (B) and ex-vivo electrically-induced (C) gCaMP3 transients in implanted PreD
and UnD engineered muscle with time PI. IVC, 2 wk of in vitro culture, prior to implantation.
Representative tetanus force traces (D) and quantified (E) twitch and tetanus force amplitudes
for PreD and UnD muscle cultured in vitro (IVC) or explanted at 1 wk PI and 2 wk PI. Mean ±
SEM; n = 6-12 bundles per group; #P < 0.05 and ##P < 0.001 between PreD and UnD group at
12
same time-point; *P < 0.05 and **P < 0.001 compared to PreD IVC group; P < 0.05 and P <
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1) SI Materials and Methods 
 
Cell Isolation and GCaMP3 Transduction. Muscle tissue from the lower hind limbs of 2-3-d-
old Sprague-Dawley rats was digested with 1 mg/mL collagenase (Worthington) and 2% 
dispase ((v/v), BD) in Wyles solution (Table S1) for 1 h at 37°C on a rocker, as previously 
described (1). Isolated cells were resuspended in growth medium (Table S1), and preplated for 
2 h at 37°C to reduce fraction of faster-adhering fibroblasts. The supernatant was then seeded 
on Matrigel coated flasks, and following day cells were reconstituted in growth media, 
transduced with a GCaMP3 lentivirus, and after 24 h, detached by 2% dispase (v/v) and used 
for generation of engineered muscle bundles. The implanted GCaMP3+ muscle bundles were 
identified following staining with anti-GFP (Abcam) antibody. 
Engineering of Muscle Bundles. Large single muscle bundles and smaller tri-bundle muscle 
implants were formed within polydimethylsiloxane (PDMS) molds containing a single semi-
cylindrical well (1.25 cm long, 3 mm diameter) or three semi-cylindrical wells (7 mm long, 2 mm 
diameter), respectively, cast from 3D-machined Teflon masters. PDMS molds were coated with 
0.2% (w/v) pluronic (Invitrogen) to prevent hydrogel adhesion. For single bundles, two Velcro 
felts (2mm x 4mm) were pinned at ends of the wells to anchor the hydrogel. Similarly, for tri-
bundle implants, laser-cut Cerex® frames (9 mm x 9 mm, 1 mm wide rim) positioned around the 
3 wells enabled hydrogel attachment and facilitated construct handling and implantation. 
Cell/hydrogel mixture (Table S1) was injected into the PDMS wells, polymerized at 37°C for 45 
min, and cultured on a rocker at 37°C for 2-4 wk. After 4 d of culture, growth medium was 
replaced by differentiation medium (Table S1) to promote fusion and differentiation of the 
myogenic cells into myofibers. Degradation of fibrin was inhibited by 1 mg/mL aminocaproic acid 
(Sigma). Cell-mediated hydrogel compaction generated passive tension resulting in uniaxial cell 
alignment (2, 3).  
Implantation of Engineered Muscle Bundles. All animal experiments were approved by the 
Duke University ACUC. Nude mice (~10 wk of age; 22-30 g) were anesthetized by 
intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). Using aseptic 
technique, the dorsal skin was attached to a temporary "C-frame" at the center of the back. The 
skin was perforated in three locations to accommodate the screws of the chamber, and a 
circular region (~12 mm) of the forward-facing skin (i.e., cutis, subcutis, retractor and panniculus 
carnosis muscles, and associated fascia) was dissected away to accommodate the window 
proper. The forward and rearward pieces of the titanium dorsal skinfold chamber were 
assembled together from opposite sides of the skin, and a Cerex® frame with tri-bundle muscle 
constructs was laid perpendicular (verified under microscope) to the intact panniculus carnosis 
muscle of the rearward-facing skin (Fig. S12F-G), providing a source of microvessels for 
vascularization. A sterile cover glass was placed over the window and engineered tissue while 
superfusing with sterile saline solution. The chamber was then secured with suture and the “C-
frame” was removed. Post-operatively, the mouse was injected subcutaneously with 
buprenorphine (1 mg/kg) painkiller and let to recover on a heating pad (4). 
Intravital Imaging of Blood Vessels. Intravital recordings were performed in anesthetized 
mice on d 2, 5, 7, 9, 12, and 14 post-implantation (PI). Mice were anesthetized by nose cone 
inhalation of isoflurane and positioned on a heating pad under a microscope objective. 
Hyperspectral brightfield image sequences (10 nm increments from 500 – 600 nm) were 
captured at 5x magnification using a tunable filter (Cambridge Research & Instrumentation, Inc.) 
and a DVC camera (ThorLabs), as previously described (4). A custom MATLAB (MathWorks) 
script was applied to create maps of total hemoglobin concentration (Fig. S15). Obtained maps 
were further processed using local contrast enhancement in ImageJ (FIJI) and thresholded to 
binary images to identify vessel area and calculate blood vessel density (BVD, total area of 
blood vessels per bundle area). 
Intravital Imaging of Intracellular Ca2+ Transients. Intravital imaging of spontaneous Ca2+ 
transients was performed immediately after vessel imaging with mice still anesthetized. 
Fluorescent GCaMP3 signals in implanted bundles were video-imaged through a FITC-filter 
using a fast fluorescent camera (Andor; at 16 µm spatial and 20 ms temporal resolution). 
Amplitudes of spontaneous Ca2+ transients were determined using the Solis software (Andor) by 
averaging relative fluorescence intensity (ΔF/F) from three ~400x400 µm2 regions within each 
bundle (Fig. S12C) (5). 
In Vitro and Ex Vivo Measurements of Ca2+ Transients. Electrically-induced GCaMP3 Ca2+ 
transients were imaged in engineered muscle bundles after 2 and 14 d of in vitro culture and in 
muscle explants 1 and 2 wk PI. Engineered muscle constructs were transferred into a custom 
chamber mounted on an inverted fluorescence microscope (Nikon), placed in 37°C Tyrode’s 
solution (Table S1), and electrically stimulated (10 ms pulse, 3 V/mm). Induced GCaMP3 
signals were recorded using a fast fluorescent camera Andor iXon 860 EMCCD (24 µm spatial 
and 20 ms temporal resolution) and analyzed as described for intravital assessment. Kinetics of 
Ca2+ transients were also characterized as previously described (5). 
Immunostaining. Cultured cells were fixed in 4% paraformaldehyde (PFA, 15 min, RT). Whole 
muscle constructs and native muscle tissues were fixed overnight (4°C) in 2% PFA. Fixed 
samples were washed in PBS, and placed in blocking solution (Table S1) overnight (4°C). 
Samples were incubated in primary antibodies (Table S2) for 24 h (4°C), washed in PBS, and 
incubated in secondary antibodies (Table S2) for 2 h (37°C). Images were acquired using a 
Zeiss confocal microscope. Tissues used for cross-sectional staining were embedded in 
paraffin, sectioned (5 µm), washed with xylene, rehydrated, microwaved 5 times for 3 m in a 
citrate buffer solution (Table S1), and immunostained. 
Analysis of Nuclear Counts. To automate nuclear counting, we utilized a custom MATLAB 
image processing program (6) that allows user-thresholding of DAPI or transcription factor 
(Pax7, Ki67, MyoD, myogenin) staining and, based on the median size of nuclei for a given 
magnification, designates and counts identified nuclei. The program outputs the processed 
images with identified nuclei for the manual verification by user. 
Analysis of Myofiber and Blood Vessel Alignment. Orientation of muscle fibers (marked by 
expression of GFP or F-actin) and blood vessels (marked by expression of CD31) was 
quantified in engineered muscle implants and native muscle from confocal images acquired at 
20x magnification using a previously described image intensity gradient algorithm (3, 6). Local 
feature orientation was calculated within 25x25 pixel (11x11 µm) subregions (Fig. S8) in which 
myofibers or blood vessels were present and standard vessel angle deviation and absolute 
mean fiber angle difference between myofiber and vessel directions were calculated by 
averaging subregion data over the entire (450x450 µm) image. Four images were analyzed per 
each muscle sample. 
Statistics. Results are presented as mean ± SEM. Statistical significances among different 
groups were evaluated by unpaired t-test or one-way ANOVA with post hoc Tukey’s test using 
GraphPad Prism (GraphPad Software, Inc.). P<0.05 was consider statistically significant. 
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2) SI Tables. 
Table S1. Cell Culture Media and Solutions 
  Name Details 
Blocking solution 5% chicken serum, 0.2% Triton-X (Sigma) 
Cell/hydrogel mixture 
10 million cells/mL, 2x growth medium, 4 mg/mL bovine fibrinogen 
(Sigma), Matrigel (20% v/v)), thrombin (0.2 unit/mg fibrinogen, Sigma) 
Citrate Buffer Solution 90% H2O, 8% 100mM Sodium Citrate, 2% 100mM Citric Acid 
Differentiation Medium 
DMEM, 3% (v/v) horse serum, 50 unti/mL penicillin G, 50 ug/mL 
strepomycin, 5 ug/mL gentamicin 
Growth Medium 
Dulbecco's modified Eagle's medium (DMEM), 10% (v/v) fetal bovine 
serum, 50 unti/mL penicillin G, 50 ug/mL strepomycin, 5 ug/mL 
gentamicin 
Tyrode's Solution 
135 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl, 1 mM MgCl, 0.33 mM 
NaHPO, 5 mM HEPES, 5 mM glucose 
Wyles Solution 
137 mM NaCl, 5 mM KCl, 21 mM HEPES, 0.7 mM Na2HPO4, 100 mM 
glucose, 0.1 mg/mL BSA 
 
 
Table S2. Antibody List       
Primary Epitope Dilution Supplier 
Catalog 
no. 
Pax7 1:15 Developmental Studies Hybridoma Bank Pax7-s 
MyoD 1:200 BD Pharmingen 554130 
myogenin 1:200 Santa Cruz Biotechnology sc-576 
sarcomeric α-actinin  1:200 Sigma a7811 
collagen IV 1:300 Abcam ab6586 
laminin 1:300 Abcam ab11575 
vimentin 1:400 Sigma v6630 
CD31 1:300 Abcam ab28364 
VWF 1:200 Abcam ab6994 
Ki67  1:200 Abcam  Ab15580 
Secondary Epitope Dilution Supplier 
Catalog 
no. 
Alexa Fluor 488 Phalloidin 1:300 Life Technologies A12379 
Alexa Fluor 594 Chicken 
Anti-Mouse IgG 
1:200 Life Technologies A21201 
Alexa Fluor 594 Chicken 
Anti-Rabbit IgG 
1:201 Life Technologies A21442 
Alexa Fluor 647 Chicken 
Anti-Mouse IgG 
1:202 Life Technologies A21463 
Alexa Fluor 488 Chicken 
Anti-Mouse IgG 
1:203 Life Technologies A21200 
 
3) SI Figures 
Fig. S1. Input cell population for engineering of skeletal muscle bundles. (A) 
Representative immunostaining of Pax7+, MyoD+, and myogenin (MyoG)+ cells. (B-C)  No 
α-smooth muscle actin (SMA)+ smooth muscle cells (A) or CD31+ endothelial cells (B) 
were present in the cell isolates. Insets, positive controls for SMA and CD31 antibodies 
showing a blood vessel in adult rat cardiac muscle (A) and capillaries in native neonatal 
rat skeletal muscle (B). (D) Quantified fractions of myogenic (Pax7+, MyoD+, MyoG+) and 
vasculogenic (SMA+, CD31+) cells used for engineering of skeletal muscle (n = 3 cell 
isolations). Stainings suggest that cell population consists primarily of activated satellite 
cells (SCs), a proliferative population of Pax7+/MyoD+ cells that can either commit to a 
myoblast fate (Pax7-/MyoD+) or revert to the quiescent state (Pax7+/MyoD-) characteristic 






































Fig. S2. Structural organization of engineered muscle bundles. (A) Representative image of 
the exterior of a 2-wk old engineered muscle bundle showing an outer layer of vimentin+ 
fibroblasts; inset: staining of the epimysial region of the neonatal rat soleus muscle showing 
similar fibroblast abundance. (B) Representative image of the interior of a 2-wk old engineered 
muscle bundle consisting of aligned striated myofibers and abutting Pax7+ satellite cells (SCs) 
residing within a laminin-rich (Lam) matrix; inset: close-up of neonatal rat soleus muscle showing 
similar position of SCs beneath basal lamina. (C) Representative image of the distribution of SCs 
and myonuclei (MyoG+ nuclei) in a 2-wk old engineered muscle bundle. 
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Fig. S3. Acquisition of homeostatic cell composition within engineered muscle bundles. 
(A) Representative images of Pax7 and Ki67 expression inside the engineered muscle 
bundles at early fusion (2d) and late post-differentiation (14d) times during in vitro culture. (B) 
Quantified fractions of Pax7+ and/or Ki67+ cells at 2 and 14 days of culture. Note a 
homeostatic shift to a non-proliferative quiescent muscle phenotype at 14d of culture. (C) 
Representative MyoD and myogenin (MyoG) expression inside the engineered muscle 
bundles at 2 and 14 days of culture. Note that abundant expression of MyoD in early fusing 
myofibers at culture day 2 is significantly decreased with the formation of mature myofibers by 
day 14. (D) Quantified fractions of MyoD+ and/or MyoG+ cells demonstrate switch to a mature, 
differentiated muscle phenotype. Mean ± SEM; n = 3-6 bundles per group; P*<0.05 compared 
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Fig. S4. Myofiber hypertrophy in engineered muscle bundles. (A,B) 
Representative images of the steady increase in myofiber diameter (A) and decrease 













Fig. S5. Functional characterization of engineered muscle bundles. (A) 
Representative active force traces in 2-wk old engineered muscle bundles showing 
increase in active force amplitude and generation of tetanic contraction at increased 
frequency of electrical stimulation. (B) Representative twitch force traces in 2-wk old 
engineered muscle bundles showing changes in active twitch and passive tension 
amplitudes with increase in engineered muscle length L (relative to initial length L0). (C) 
Amplitude of passive tension at 10% strain (L/L0=1.1). (D) Ratio of active tetanus force 
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Fig. S6. Regeneration of engineered muscle bundles following cardiotoxin injury 
in vitro. (A-C) Representative images of proliferating satellite cells (Pax7+/Ki67+) (A), 
MyoD (B), and myogenin (MyoG) (C) in 2-wk old engineered muscle bundles prior to 
cardiotoxin (CTX) administration and 6 hours, 5 days, and 10 days after CTX injury. (D) 
Representative images of the immediate sarcomere destruction following CTX injury 
and the gradual recovery of sarcomeric structures over the following 10 days of culture.  





















Fig. S7. Structural characterization of 2-day old undifferentiated engineered (UnD) 
muscle bundles. (A) Vimentin (Vim)+ fibroblasts were predominantly found at the exterior of 
the bundle. (B-C) Non-fused or newly fusing myogenic cells as well as short immature 
myotubes were found within the interior of bundle (B), along with Pax7+ cells and a laminin 
(Lam)-rich matrix (C). (D) Undifferentiated myogenic cells inside the bundle were highly 
proliferative, as evident by the abundant expression of Ki67. 
















Fig. S8. Vascular organization in implanted engineered muscle bundles. (A) Representative 
images of CD31+ blood vessels and GFP+ myofibers in the interior and periphery of the pre-
differentiated (PreD) muscle bundles at 2 wk post-implantation (PI). (B) Processed panel A (right) 
showing separated green and red channels with local myofiber and vessel directions quantified 
within individual 25x25 pixel (11x11 µm) regions. The close-up inset shows mean direction (angle) 
of alignment within each pixel denoted by a thin line. (C) Representative images of CD31+ vessels in 
the interior of neonatal and adult muscle. (D) Standard deviations of vessel alignment within the 
interior and periphery of the 2wk PI bundles and native muscles. (E) Mean angle differences 
between average myofiber and vessel directions of alignment. Mean ± SEM; n = 4-8 samples per 
group (8-10 images per sample); P<0.05 and P<0.001 between groups denoted by solid and 
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Fig. S9. Capillary lumen diameters in implanted engineered muscle bundles. (A) Histogram 
distribution of lumen diameters within the implanted pre-differentiated (PreD) and 
undifferentiated (Und) engineered muscle at 1 wk (1wPI) and 2 wk (2wPI) post-implantation (PI) 
as well in neonatal and adult hind limb muscles. Capillary lumen diameters were measured from 
cross-sectional images immunostained with F-actin and Von Willebrand Factor (example shown 
in Figure 3E). (B) Mean lumen diameters in 6 studied groups. Mean ± SEM; n = 50-70 lumens 
per group; *P < 0.001 compared to neonatal values, #P < 0.05 compared to adult values, and P < 
0.05 between groups denoted by horizontal lines. 




































































































Fig. S10. Myogenesis and structural differentiation of implanted engineered muscle bundles. 
(A) Representative images of myofibers within implanted pre-differentiated (PreD) and 
undifferentiated (UnD) muscle bundles at 1 wk (1wPI) and 2 wk (2wPI) post-implantation. (B) 
Changes in myofiber diameter and percent of cross-striated myofibers relative to values in PreD 
bundles cultured for 2 wk in vitro (PreD-IVC). Mean ± SEM; n = 8-12 bundles (10-20 measurements 
per bundle) per group; *P<0.05 and **P<0.001 compared to PreD-IVC values; P<0.01 and P<0.001 
between groups denoted by solid and dashed horizontal lines, respectively. 
Fig. S11. Myofiber alignment in pre-differentiated and undifferentiated implanted 
engineered muscle bundles. (A) Representative images of myofibers in undifferentiated 
(UnD) and pre-differentiated (PreD) engineered muscle bundles prior to implantation. (B) 
Representative images of myofiber alignment in PreD and UnD bundles at 1 (1wPI) and 2 wk 
(2wPI) post-implantation. (C) Example map of local myofiber directions within 25x25 pixel 
(11x11 µm) regions in a PreD bundle. Inset, average local angle deviation from mean myofiber 
direction (in units of deg). Note more uniform unidirectional alignment (smaller angle deviation) 
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Fig. S12. Measurements of intracellular calcium transient and contractile force 
generation in implanted engineered muscle bundles. (A) Representative brightfield and 
fluorescent images of myogenic cells transduced with GCaMP3 virus prior to assembly into a 
muscle bundle. (B) Representative GCaMP3 traces from an engineered muscle bundle at 
various stimulation frequencies. The traces are progressively shifted upwards for improved 
clarity. (C) Select time snapshots of recorded GCaMP3 fluorescence from an explanted 
muscle bundle during application of an electrical stimulus. (D) Averaged fluorescence traces 
from the red square region within the muscle bundle and blue square region (background) 
outside of the bundle shown in (C). Vertical lines denote times of the snapshots shown in (C). 
(E) ΔF/F signal amplitude is calculated using the shown formula. (F) Representative brightfield 
image of an engineered muscle bundle implanted perpendicular to the direction of underlying 
host muscle fibers within a dorsal window chamber. (G) 2 wk post-implantation, transverse 
cross-section of implanted muscle overlaying longitudinal section of host muscle confirms that 
two muscles remain perpendicular to each other. (H) Representative tetanus force traces and 
average active forces of control host muscle without implant, measured parallel and 
perpendicular to host myofiber orientation. Note that in the direction perpendicular to host 
myofiber orientation (and along the orientation of implanted muscle bundles), the active force 
generated by the host muscle is negligible. Mean ± SEM; n = 3 mice.  
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Fig S13. Kinetics of electrically-induced calcium transient and twitch force 
responses in engineered muscle bundles.  Time-to-peak (TTP), 50% relaxation, 
and 80% relaxation times of (A) recorded GCaMP3-calcium transients and (B) 
measured twitch forces during 1 Hz electrical stimulation in pre-differentiated (PreD) 
and undifferentiated (UnD) in vitro (IVC) patches and patches explanted at 1 wk 
(1wPI) and 2 wk (2wPI) post-implantation. Mean ± SEM; n = 6-10 bundles per group; 
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Fig. S14. Effect of co-encapsulation of endothelial and myogenic cells on 
function of engineered muscle bundles. Twitch and tetanus forces with varying 
concentrations of myogenic and rat aortic endothelial cells within the engineered 
muscle bundles normalized to 10 mil/mL myogenic cell group (control). Mean ± SEM; 
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Fig. S15. Method for calculating blood vessel density in implanted engineered 
muscle bundles. (A) Consistent regions of interests (ROIs) were identified within raw 
intravital images of total hemoglobin concentration for the same implanted bundle at 
different time points (days) post implantation. Using ImageJ (FIJI) software, local contrast 
was enhanced (B) and blood vessels were identified following conversion of the enhanced 
into binary images (C). From these images, the blood vessel density (i.e., total vessel area 
per bundle area) was measured in blind fashion. 
4) SI Movie Legends 
Movie S1. Engineered muscle contractions. Representative twitch and tetanus contractions 
of an unloaded, 2-week old engineered muscle bundle electrically stimulated by a single pulse 
(10 ms duration, 3 V/mm) or a 40 Hz pulse train, respectively. During culture, ends of the 
engineered muscle were attached to rectangular Velcro® felts.  
Movie S2. Ingrown neovasculature within implanted engineered muscle. Representative 
intravital recordings of ingrown neovasculature within the implanted engineered muscle (yellow 
pseudo-color region) at 7 and 14 days post-implantation. Red blood cell flow through the 
ingrown vessels and spontaneous contractions of engineered muscle are readily observed. 
Movie S3. Spontaneous tetanic contraction of implanted engineered muscle. 
Representative intravital recording of spontaneous tetanic contractions in the implanted 
engineered muscle (yellow pseudo-color regions) at 14 days post-implantation. Note that during 
tetanic contraction, blood flow in the ingrown capillaries appears to be transiently haltered. 
Movie S4. In vivo recordings of Ca2+ transients. Representative intravital recordings of 
GCaMP3-reported spontaneous Ca2+ transients in the implanted pre-differentiated (PreD) and 
undifferentiated (UnD) engineered muscle bundles (yellow pseudo-color regions) at 14 days 
post-implantation. Note asynchronous firing of spontaneous Ca2+ transients (GCaMP3 flashes) 
in different myofibers within the implants. Stronger flashes are followed by more forceful 
contractions. 
Movie S5. Ex vivo recordings of Ca2+ transients. Representative recordings of GCaMP3-
reported, electrically-induced Ca2+ transients in the PreD and UnD engineered muscles 
explanted 14 days post-implantation. Single electrical pulse (10 ms duration, 3 V/mm) induces 
synchronized, spatially uniform firing of Ca2+ transient (GCaMP3 flash) rapidly followed by 
strong twitch contraction. 
